Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 4Febrile Neutropenia 3Neoplasms, Plasma Cell 2Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia 2Infections 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1PDAC - Pancreatic Ductal Adenocarcinoma 1Neutropenia 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Colorectal Neoplasms 1

Interventions

sipuleucel-T 2enzalutamide 2gallium 68 PSMA-11 1Vancomycin 1Metronidazole 1Docetaxel 1Ciprofloxacin 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-Resistant Prostate Cancer (mCRPC) × Ciprofloxacin × 1 year × Clear all
NCT06126731 2025-11-24

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting
39 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡